
FDA Approves New Lung Cancer Drug for Younger Patients
A breakthrough lung cancer treatment targeting a rare genetic mutation just won FDA approval two months ahead of schedule. The drug offers new hope for younger patients, often in their 40s and 50s, whose cancer stopped responding to earlier treatments.





%2Ffile%2Fattachments%2F2995%2F12866080_256720.jpg)
%2Ffile%2Fattachments%2Forphans%2FTL_2489789_604634.jpg)

